logo
  

CVS Pharmacy To Offer Pfizer-BioNTech's COVID-19 Pediatric Vaccine Starting On Sunday

CVS Health (CVS) said that certain CVS Pharmacy will offer a two-dose primary series of the Pfizer-BioNTech COVID-19 pediatric vaccine to children ages five to 11 years of age starting on Sunday.

It follows authorization of the vaccine by the Centers for Disease Control and Prevention (CDC) based on guidance from the organization's Advisory Committee on Immunization Practices and Food and Drug Administration (FDA) Emergency Use Authorization.

The vaccine will be available at nearly 1,700 CVS Pharmacy locations in 46 states, Puerto Rico and Washington D.C., the company said.

In a separate press release, Rite Aid said it is prepared to begin administering doses of Pfizer-BioNTech's COVID-19 pediatric vaccine to children aged 5-11 as soon as the 10 microgram doses are distributed to Rite Aid, which is expected at the end of this week.

The first available appointments for age 5-11 doses will be on Saturday, November 6. Those appointments may be booked through our scheduling tool beginning Thursday, November 4.

The Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age is administered as a two-dose primary series, 3 weeks apart, but is a lower dose (10 micrograms) than that used for individuals 12 years of age and older (30 micrograms).

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of LM Ericsson were gaining more than 7 percent in Swedish trading as well as in pre-market activity on Nasdaq, after the telecom equipment maker reported Tuesday higher profit and sales in its fourth quarter with strong demand. Further, the company lifted its full-year dividend, and maintained targets for fiscal 2022 EBIT growth as well as long-term target of EBITA margin. Twitter Inc. said it is expanding engineering center in Singapore, its Asia Pacific headquarters. The number of engineers there will be doubled to over 100 staff in 2023. Focused on product innovations and improvements, the new hires will work from Singapore on global initiatives for Twitter. These new technical hires will span roles in engineering, data science, machine learning and product... The U.S. Food and Drug Administration (FDA) has granted approval and reissued the revised Emergency Use Authorization (EUA) to Gilead Sciences Inc. for antiviral drug Veklury (remdesivir) to treat certain non-hospitalized adults and pediatric patients with mild-to-moderate COVID-19 disease.
Follow RTT